Press Releases

<>

February 20, 2018

Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Real Endpoints plays a valuable role in orchestrating a first-of-its-kind value-based contract between Harvard Pilgrim and Illumina by introducing the parties and helping to craft the deal structure. Real Endpoints will provide all analytics and financial reconciliation for the initiative.

read full press release >

July 17, 2017

Real Endpoints appoints Jane F. Barlow, MD, EVP and Chief Clinical Officer

Real Endpoints (RE), a data, analytics, and advisory company that helps payers and biopharma companies define the value and economic impact of new pharmaceuticals and value-based approaches to reimbursement, announced today that Jane F. Barlow, MD, MPH, MBA, a 25-year veteran of healthcare payers, has joined the company as Executive Vice President and Chief Clinical Officer. Dr. Barlow will lead RE’s advisory work as well as applications of its assessment tools.

read full press release >

January 31, 2017

Survey finds variability in MS treatment preferences among individual patients, and among stakeholder groups

Real Endpoints, LLC (RE), a data and analytics firm that assesses and quantifies pharmaceutical value, has just completed an extensive literature review and survey to tease out how different stakeholder groups assess the value of current multiple sclerosis (MS) therapies.

read full press release >

March 10, 2016

A Tale of Two New Hepatitis C Drugs

Despite discount, Merck’s just approved Zepatier unlikely to win share with most US payers, except in Medicaid, according to RxScorecard™. New combo from Gilead could ensure company’s dominant position among US payers.

read full press release >

February 11, 2016

Real Endpoints’ RxScorecard™ predicted launch failure of major new anti-cholestrol drugs

Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened.

read full press release >

July 7, 2015

PCSK9 class could have major impact on budgets but lack of data and comparability of drugs will allow aggressive payers to control costs: RxScorecard™ analysis

According to Real Endpoints’ (RE) just-released RxScorecard™ analysis of the new lipid-lowering therapies, the innovative PCSK9 inhibitors which could be highly valuable for patients with difficult-to-lower, high LDL-C (bad cholesterol) levels, are both comparable to each other and lack key data that would justify broader use. The implications: payers will have an extraordinary opportunity to control costs in this class, which many analysts have predicted could far surpass hepatitis C treatment costs.

read full press release >